CLRN3

Across TCGA pan-cancer cohorts, CLRN3 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CLRN3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CLRN3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CLRN3 is over-expressed in tumor, although a few such as KICH and LIHC show the opposite, repressed pattern.

KIRC, STAD, and THCA are the cancer types where CLRN3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLRN3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+2.983	<.001	12	view →
STAD	Female	All	+4.315	<.001	10	view →
THCA	Male	III,IV	+0.830	<.001	10	view →
KICH	Female	All	−3.825	<.001	9	view →
LIHC	Male	II,III,IV	−2.306	<.001	8	view →
LUSC	Female	II,III,IV	−0.294	<.001	8	view →
COAD	Female	All	−0.986	<.001	5	view →
CHOL	All	All	−1.464	.010	4	view →
BRCA	Female	All	−0.208	<.001	4	view →
LUAD	All	All	+0.321	.009	3	view →
PAAD	All	All	+2.507	.044	2	view →
ESCA	All	All	+3.142	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CLRN3–KIRC

Open the KIRC breakdown →